Researcher Profile

Researcher Profile

Sheldon Holder, PhD, MD

Sheldon Holder, PhD, MD

Assistant Professor, Department of Medicine
Division of Hematology and Oncology
Scientific Program:Next-Generation Therapies
Disease Teams:
Genitourinary Cancer
slh51@psu.edu

Research Interests

  • Neoplasms
  • Therapeutics
  • Phosphotransferases
  • Prostatic Neoplasms
  • Carcinoma
  • Survival
  • Drug Therapy
  • Renal Cell Carcinoma
  • DNA Damage
  • Smokers
  • Castration
  • Urinary Bladder Neoplasms

Clinical Trials

A Phase III Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib plus JNJ-63723283 (Cetrelimab), an Anti-PD-1 Monoclonal Antibody, in Subjects with Metastatic or Locally Advanced Urothelial Cancer with Selected FGFR Gene Alterations
APG-115 - A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors
Phase III Randomized Trial Of Concurrent Chemoradiotherapy With or Without Atezoluzumab in Localized Muscle Invasive Bladder Cancer
Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Phase 2 Study of Bladder-SparIng ChemoradiatioN with CIPosItive bladdeR cancEr (INSPIRE)EA8185
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Renal Cell Cancer (PDIGREE)
A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
Follow up for patients on Phase lb Clinical Trial of Eribulin Mesylate and the PD-Ll Monoclonal Antibody, Avelumab, in Cisplatin Ineligible or Platinum Resistant Metastatic Urothelial Cell Cancer
NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging Into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy
Observational Study to Determine the Differences in Molecular Characterization between Smokers vs. Non-smokers in Patients with Stage IV Bladder Cancer and their Correlation with Clinical Outcome

Recent Publications

2021

Joshi, M, Holder, SL, Zhu, J, Zheng, H, Komanduri, S, Warrick, J, Yasin, H, Gajre, R, Jia, B, Drabick, J, Degraff, D & Zakharia, Y 2021, 'Avelumab in Combination with Eribulin Mesylate in Metastatic Urothelial Carcinoma: BTCRC GU-051, a Phase 1b Study', European Urology Focus. https://doi.org/10.1016/j.euf.2021.03.005

2020

Joshi, M, Grivas, P, Mortazavi, A, Monk, P, Clinton, SK, Sue-Ann Woo, M, Holder, SL, Drabick, JJ & Yin, M 2020, 'Alterations of DNA damage response genes correlate with response and overall survival in anti-PD-1/PD-L1-treated advanced urothelial cancer', Cancer medicine, vol. 9, no. 24, pp. 9365-9372. https://doi.org/10.1002/cam4.3552
Yin, M, Grivas, P, Wang, QE, Mortazavi, A, Emamekhoo, H, Holder, SL, Drabick, JJ, Woo, MSA, Pal, S, Vasekar, M, Folefac, E, Clinton, SK, Monk, P & Joshi, M 2020, 'Prognostic Value of DNA Damage Response Genomic Alterations in Relapsed/Advanced Urothelial Cancer', Oncologist, vol. 25, no. 8, pp. 680-688. https://doi.org/10.1634/theoncologist.2019-0851

2019

Zaleski, M, Gogoj, A, Walter, V, Raman, JD, Kaag, M, Merrill, SB, Drabick, J, Joshi, M, Holder, S, DeGraff, DJ & Warrick, JI 2019, 'Mitotic activity in noninvasive papillary urothelial carcinoma: its value in predicting tumor recurrence and comparison with the contemporary 2-tier grading system', Human Pathology, vol. 84, pp. 275-282. https://doi.org/10.1016/j.humpath.2018.10.008
Joshi, M, Warrick, JI, Yin, M, Holder, SL & Drabick, JJ 2019, 'Need for a personalized approach for muscle invasive bladder cancer: Role of tumor biology in response to neoadjuvant chemotherapy', Translational Andrology and Urology, vol. 8, pp. S99-S103. https://doi.org/10.21037/tau.2018.12.04
Wang, M, Chi, G, Bodovski, Y, Holder, SL, Lengerich, EJ, Wasserman, E & McDonald, AC 2020, 'Temporal and spatial trends and determinants of aggressive prostate cancer among Black and White men with prostate cancer', Cancer Causes and Control, vol. 31, no. 1, pp. 63-71. https://doi.org/10.1007/s10552-019-01249-0

2017

Small, J, Washburn, E, Millington, K, Zhu, J & Holder, SL 2017, 'The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors', Oncotarget, vol. 8, no. 56, pp. 95116-95134. https://doi.org/10.18632/oncotarget.19618

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)